Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000429991 | SCV000510762 | uncertain significance | not provided | 2016-09-28 | criteria provided, single submitter | clinical testing | Converted during submission to Uncertain significance. |
Gene |
RCV000607638 | SCV000719304 | likely benign | not specified | 2017-05-09 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV000652817 | SCV000774689 | likely benign | Noonan syndrome 9 | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003168619 | SCV003911934 | uncertain significance | Cardiovascular phenotype | 2024-03-12 | criteria provided, single submitter | clinical testing | The c.3235A>G (p.T1079A) alteration is located in exon 20 (coding exon 20) of the SOS2 gene. This alteration results from a A to G substitution at nucleotide position 3235, causing the threonine (T) at amino acid position 1079 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |